fam-trastuzumab deruxtecan-nxki
Enhertu Approved for Unresectable or Metastatic HER2-positive Solid Tumors
The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for adult ...
APRIL 8, 2024
FDA Approves Enhertu to Treat Gastric and GEJ Adenocarcinomas
The FDA approved approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo/AstraZeneca) for adults with ...
JANUARY 29, 2021
Enhertu: New Option for Previously Treated Unresectable or Metastatic HER2+ Breast Ca
The FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo) for the treatment ...
JANUARY 7, 2020
Load more